Bank of New York Mellon Corp Sells 9,968 Shares of Hologic, Inc. (NASDAQ:HOLX)

Bank of New York Mellon Corp decreased its stake in shares of Hologic, Inc. (NASDAQ:HOLX – Get Rating) by 0.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,074,559 shares of the medical equipment provider’s stock after selling 9,968 shares during the period. Bank of New York Mellon Corp’s holdings in Hologic were worth $133,851,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HOLX. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in Hologic by 5.1% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 33,448 shares of the medical equipment provider’s stock valued at $2,569,000 after purchasing an additional 1,631 shares during the period. LSV Asset Management lifted its position in Hologic by 307.5% during the first quarter. LSV Asset Management now owns 37,900 shares of the medical equipment provider’s stock valued at $2,911,000 after purchasing an additional 28,600 shares during the period. Raymond James Trust N.A. lifted its position in Hologic by 7.4% during the first quarter. Raymond James Trust N.A. now owns 6,875 shares of the medical equipment provider’s stock valued at $528,000 after purchasing an additional 476 shares during the period. Dimensional Fund Advisors LP lifted its position in Hologic by 4.8% during the first quarter. Dimensional Fund Advisors LP now owns 2,305,399 shares of the medical equipment provider’s stock valued at $177,098,000 after purchasing an additional 106,315 shares during the period. Finally, Aviva PLC lifted its position in Hologic by 0.7% during the first quarter. Aviva PLC now owns 75,543 shares of the medical equipment provider’s stock valued at $5,803,000 after purchasing an additional 513 shares during the period. Institutional investors own 95.17% of the company’s stock.

Insider Buying and Selling at Hologic

In other Hologic news, insider Benjamin Jordan Cohn sold 9,128 shares of the stock in a transaction on Tuesday, February 7th. The shares were sold at an average price of $85.28, for a total transaction of $778,435.84. Following the completion of the transaction, the insider now owns 14,298 shares in the company, valued at $1,219,333.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.66% of the stock is owned by company insiders.

Hologic Stock Performance

HOLX opened at $77.07 on Friday. The stock has a market capitalization of $19.00 billion, a price-to-earnings ratio of 19.66, a PEG ratio of 1.38 and a beta of 1.01. The company has a fifty day moving average of $81.03 and a 200 day moving average of $74.06. Hologic, Inc. has a fifty-two week low of $59.78 and a fifty-two week high of $86.65. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.50 and a current ratio of 4.21.

Hologic (NASDAQ:HOLX – Get Rating) last posted its earnings results on Wednesday, February 1st. The medical equipment provider reported $1.07 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.17. The company had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.01 billion. Hologic had a net margin of 22.17% and a return on equity of 25.12%. Hologic’s quarterly revenue was down 27.0% on a year-over-year basis. During the same period last year, the company posted $2.17 earnings per share. As a group, sell-side analysts forecast that Hologic, Inc. will post 3.74 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on HOLX. Citigroup increased their price objective on shares of Hologic from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Thursday, February 2nd. Morgan Stanley increased their price target on shares of Hologic from $74.00 to $81.00 and gave the stock an “equal weight” rating in a research report on Friday, February 3rd. JPMorgan Chase & Co. increased their price target on shares of Hologic from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Thursday, February 2nd. StockNews.com initiated coverage on shares of Hologic in a research report on Thursday. They issued a “buy” rating on the stock. Finally, SVB Leerink increased their price target on shares of Hologic from $90.00 to $93.00 and gave the stock an “outperform” rating in a research report on Thursday, February 2nd. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Hologic has an average rating of “Moderate Buy” and a consensus price target of $84.08.

About Hologic

(Get Rating)

Hologic, Inc engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery.